Category: Federal Forum Posters
Purpose: Glucagon-like peptide-1 receptor agonists are injectable incretin hormones approved for the treatment of type II diabetes mellitus. They are highly efficacious agents with significant hemoglobin A1c lowering potential and mechanisms of action that results in weight loss. As a result of a cost savings initiative, the pharmacy and therapeutics committee at a veterans affairs hospital established liraglutide 1.2mg as its preferred agent and converted patients from exenatide and liraglutide 1.8mg to liraglutide 1.2mg. However, the benefit of this change remains unknown. The objective of this study is to assess sustained glycemic control and cost savings that resulted from this change.
Methods: A retrospective chart review will be conducted at a veterans affairs hospital to include patients on liraglutide 1.8 mg plus insulin plus and/or minus metformin who were converted to liraglutide 1.2 mg between May 2018 and August 2018. Demographic data, hemoglobin A1c, serum glucose levels, body weights, prescriber type, and medication history will be obtained using the Computerized Patient Record System (CPRS). Patients’ charts will be evaluated over a 6-month evaluation period and descriptive statistics will be used to calculate differences in baseline characteristics and hemoglobin A1c as appropriate. Overall cost savings to the institution as a result of the therapeutics change will also be reported.
Results: not applicable
Conclusion: not applicable
Fiona Imarhia– Student, The University of Texas at Austin College of Pharmacy, Houston, TX